Hanmi Pharm Dividends and Buybacks
Dividend criteria checks 0/6
Hanmi Pharm is a dividend paying company with a current yield of 0.18%.
Key information
0.2%
Dividend yield
0.09%
Buyback Yield
| Total Shareholder Yield | 0.3% |
| Future Dividend Yield | 0.2% |
| Dividend Growth | 0.04% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | ₩500.000 |
| Payout ratio | 6% |
Recent dividend and buyback updates
Recent updates
Risks To Shareholder Returns Are Elevated At These Prices For Hanmi Pharm. Co., Ltd. (KRX:128940)
Nov 19
Does Hanmi Pharm (KRX:128940) Have A Healthy Balance Sheet?
Nov 01Does Hanmi Pharm (KRX:128940) Deserve A Spot On Your Watchlist?
Oct 17Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 36% Below Their Intrinsic Value Estimate
Aug 16Pinning Down Hanmi Pharm. Co., Ltd.'s (KRX:128940) P/E Is Difficult Right Now
Jul 31Do Hanmi Pharm's (KRX:128940) Earnings Warrant Your Attention?
Jul 16Hanmi Pharm (KRX:128940) Seems To Use Debt Rather Sparingly
Jun 11A Look At The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)
May 08Hanmi Pharm. Co., Ltd.'s (KRX:128940) Share Price Not Quite Adding Up
Apr 22Calculating The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)
Mar 15Hanmi Pharm (KRX:128940) Use Of Debt Could Be Considered Risky
Feb 16
What Percentage Of Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Do Insiders Own?
Jan 17Hanmi Pharm's (KRX:128940) Stock Price Has Reduced 48% In The Past Five Years
Dec 22Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 22% Below Their Intrinsic Value Estimate
Nov 24Stability and Growth of Payments
Fetching dividends data
Stable Dividend: A128940 is not paying a notable dividend for the KR market, therefore no need to check if payments are stable.
Growing Dividend: A128940 is not paying a notable dividend for the KR market, therefore no need to check if payments are increasing.
Dividend Yield vs Market
| Hanmi Pharm Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (A128940) | 0.2% |
| Market Bottom 25% (KR) | 1.2% |
| Market Top 25% (KR) | 3.9% |
| Industry Average (Pharmaceuticals) | 1.1% |
| Analyst forecast (A128940) (up to 3 years) | 0.2% |
Notable Dividend: A128940's dividend (0.18%) isn’t notable compared to the bottom 25% of dividend payers in the KR market (1.24%).
High Dividend: A128940's dividend (0.18%) is low compared to the top 25% of dividend payers in the KR market (3.92%).
Earnings Payout to Shareholders
Earnings Coverage: A128940 is not paying a notable dividend for the KR market.
Cash Payout to Shareholders
Cash Flow Coverage: A128940 is not paying a notable dividend for the KR market.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 11:32 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hanmi Pharm. Co., Ltd. is covered by 32 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dae Woong Yoo | Bookook Securities Co. Ltd |
| Seohyun Lee | Citigroup Inc |
| Hyonseok Kim | CLSA |